January 27, 2022，Sun Pharma announced the launch of CEQUA, a new treatment for Canadians living with dry eye disease. CEQUA (cyclosporine ophthalmic solution 0.09% w/v), is the first dry eye treatment available in Canada that is delivered with nanomicellar (NCELL) technology, which improves the bioavailability and physicochemical stability of cyclosporine to increase ocular tissue penetration.
“We are excited to introduce CEQUA as a new treatment option for the more than six million Canadians living with dry eye disease,” said Abhay Gandhi, CEO North America, Sun Pharma. “This launch is an important milestone for Sun Pharma as we expand our ophthalmics portfolio into Canada.”
A recent report from Centre for Ocular Research & Education(CORE) has shown that rates of dry eye disease are on the rise due to an increase in mask wearing, which can lead to dry spots on the ocular surface.
Further information can be found in the original press release：https://sunpharma.com/wp-content/uploads/2022/01/Press-Release-Sun-Pharma-launches-CEQUA-in-Canada.pdf